IGCNYSEPharmaceutical PreparationsFiscal year ends December 31

IGC Pharma, Inc.

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.24−0.00 (-1.63%)

Close on Oct 19, 2026

Market cap: $24.28M
P/E (TTM): –
Dividend yield: –

Dividends

IGC Pharma has not reported a dividend

No dividend per share appears in IGC Pharma's annual filings since fiscal 2012.

Where these numbers come from

Parsed from the XBRL in IGC Pharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-1062 reverse split on Oct 16, 2018
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IGC.

Revenue growth-15.4% · median -42.7%

Gross margin21.9% · median 61.4%

Operating margin-986.8% · median -4023.8%

Net margin-702.1% · median -9160.9%

Company	Revenue	Growth
ACIU	CHF 3.94M	–
LGVN	$1.19M	-42.7%
IGC	$1.12M	-15.4%
BTAIQ	$742.00K	-14.5%
CRVO	$331.30K	-95.7%
SPRB	–	–

Company

Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 67
Held by institutions: 5.1%
Auditor: Manohar Chowdhry & Associates
SEC CIK: 1326205

Advertisement
300 × 250